View Future Growth3SBio 過去の業績過去 基準チェック /663SBioは、平均年間32.3%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間33.8% 17.8%収益成長率で 成長しています。 3SBioの自己資本利益率は29.9%であり、純利益率は47.9%です。主要情報32.27%収益成長率33.33%EPS成長率Biotechs 業界の成長17.04%収益成長率17.81%株主資本利益率29.89%ネット・マージン47.93%前回の決算情報31 Dec 2025最近の業績更新お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023すべての更新を表示Recent updatesお知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.お知らせ • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.お知らせ • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024お知らせ • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.お知らせ • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023お知らせ • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.お知らせ • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.お知らせ • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.お知らせ • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.収支内訳3SBio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:TRSB.F 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費31 Dec 2517,6968,4824,2821,52030 Sep 2513,3855,4204,1201,45930 Jun 259,0742,3593,9571,39831 Mar 259,0912,2243,9051,36231 Dec 249,1082,0903,8531,32730 Sep 248,7651,8743,7731,14530 Jun 248,4221,6593,69396431 Mar 248,1191,6043,59088031 Dec 237,8161,5493,48779530 Sep 237,6861,7393,35175030 Jun 237,5551,9293,21570631 Mar 237,2101,9233,09470031 Dec 226,8661,9162,97469430 Sep 226,6181,8172,84969930 Jun 226,3691,7192,72570331 Mar 226,3761,6852,71072931 Dec 216,3821,6512,69675430 Sep 216,1911,3422,68871730 Jun 216,0001,0322,68168131 Mar 215,7949342,57763631 Dec 205,5888362,47259030 Sep 205,4791,0952,53558130 Jun 205,3701,3552,59857131 Mar 205,3441,1642,61254931 Dec 195,3189742,62752730 Sep 195,1851,0292,40954930 Jun 195,0531,0842,19057231 Mar 194,8181,1812,09946831 Dec 184,5841,2772,00836330 Sep 184,3931,1671,91118130 Jun 184,2021,0571,814031 Mar 183,9689961,731031 Dec 173,7349351,648030 Sep 173,4678771,601030 Jun 173,1998181,555031 Mar 172,9987661,437031 Dec 162,7977131,318030 Sep 162,4926421,104030 Jun 162,188571889031 Mar 161,930548800031 Dec 151,673526710030 Sep 151,503456676030 Jun 151,3643417440質の高い収益: TRSB.Fは 高品質の収益 を持っています。利益率の向上: TRSB.Fの現在の純利益率 (47.9%)は、昨年(23%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TRSB.Fの収益は過去 5 年間で年間32.3%増加しました。成長の加速: TRSB.Fの過去 1 年間の収益成長率 ( 305.8% ) は、5 年間の平均 ( 年間32.3%を上回っています。収益対業界: TRSB.Fの過去 1 年間の収益成長率 ( 305.8% ) はBiotechs業界43%を上回りました。株主資本利益率高いROE: TRSB.Fの 自己資本利益率 ( 29.9% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 05:58終値2026/05/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋3SBio Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関Bo YuChina International Capital Corporation LimitedZhuhong ChenChina Merchants Securities (HK) Co., LtdShitong HanCitic Securities Co., Ltd.32 その他のアナリストを表示
お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025
お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023
お知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.
お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.
お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055
お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.
お知らせ • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.
お知らせ • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.
お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025
お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.
お知らせ • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.
お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.
お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023
お知らせ • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.
お知らせ • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.
お知らせ • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.
お知らせ • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.